Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 3, 2014, Pages 923-931

  Du, Yue Feng ^a   Long, Qing Zhi ^a   Shi, Ying ^b   Liu, Xiao Gang ^a   Li, Xu Dong ^a   Zeng, Jin ^a   Gong, Yong Guang ^a   Wang, Xin Yang ^a   He, Da Lin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; mTOR; Prostatic carcinoma

Indexed keywords

MTOR PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANIMAL; CELL PROLIFERATION; DOWN REGULATION; DRUG SCREENING; GENE SILENCING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; MALE; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LENTIVIRUS; MALE; MICE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899526280     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A and Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241.
3. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
4. Yang Q and Guan KL. Expanding mTOR signaling. Cell Res 2007; 17: 666-681.
5. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P and Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457-468.
6. Efeyan A and Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22: 169-176.
7. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
8. Guertin DA and Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
9. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
10. Corradetti MN and Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006; 25: 6347-6360.
11. Nguyen DG, Yin H, Zhou Y, Wolff KC, Kuhen KL and Caldwell JS. Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening. Virology 2007; 362: 16-25.
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
13. Tiscornia G, Singer O, Ikawa M and Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 2003; 100: 1844-1848.
14. Bos TJ, De Bruyne E, Heirman C and Vanderkerken K. In search of the most suitable lentiviral shRNA system. Curr Gene Ther 2009; 9: 192-211.
15. Guertin DA and Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11: 353-361.
16. Voss MH, Molina AM and Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 835-852.
17. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD and Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007; 25: 209-226.